These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS; Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957 [TBL] [Abstract][Full Text] [Related]
10. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Cunningham ET; Adamis AP; Altaweel M; Aiello LP; Bressler NM; D'Amico DJ; Goldbaum M; Guyer DR; Katz B; Patel M; Schwartz SD; Ophthalmology; 2005 Oct; 112(10):1747-57. PubMed ID: 16154196 [TBL] [Abstract][Full Text] [Related]
11. Pegaptanib for branch retinal vein occlusion. Wong I; Koo S; Chan C Am J Ophthalmol; 2010 Jul; 150(1):129; author reply 129-30. PubMed ID: 20609713 [No Abstract] [Full Text] [Related]
12. The effect of pegaptanib (Macugen(®) ) injection on retinal and retrobulbar blood flow in retinal Ischaemic diseases. Hussain RM; Harris A; Siesky B; Yung CW; Ehrlich R; Prall R Acta Ophthalmol; 2015 Aug; 93(5):e399-e400. PubMed ID: 25639282 [No Abstract] [Full Text] [Related]
13. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]